In Immunology, J&J Makes A Big Move On Biologic Combinations
Executive Summary
The company has initiated a Phase II study of Tremfya and Simponi in combination for the treatment of ulcerative colitis, J&J's first human study of two targeted immunology drugs together.
You may also be interested in...
Lilly Advances IL-23, Gastroenterology Ambitions With Mirikizumab In Crohn's Disease
The company reported positive Phase II results and will move its potential fourth-to-market IL-23 inhibitor into Phase III in Crohn's disease later this year. Mirikizumab – in Phase III for psoriasis and ulcerative colitis – may be the second IL-23 drug for an IBD indication.
J&J Plans 10 Potential Blockbuster Filings By 2023
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.